FRAXA’s mission is to discover specific treatments and ultimately a cure for Fragile X syndrome, aiming to transition practical treatment into current medical practice quickly. They prioritize projects with clear, practical applications, emphasizing results sharing in a timely manner. By funding research grants and fellowships globally and partnering with biomedical and pharmaceutical companies, FRAXA bridges the gap between research discoveries and treatments, benefiting individuals affected by Fragile X and potentially those with autism, Alzheimer's, and other brain disorders.
FRAXA Research Foundation focuses on advancing research that promises to lead to new and improved treatments and ultimately a cure for Fragile X syndrome. They place particular importance on disease-modifying therapeutics derived from an understanding of Fragile X disease mechanisms. The foundation supports clinical trials as its highest priority, alongside translational research and early-stage investigations. FRAXA adapts its funding priorities based on the current research landscape and past bottlenecks in the research process, with a historical emphasis on overcoming issues like basic disease mechanism understanding and resource constraints. Recently, FRAXA has shifted its focus towards overcoming bottlenecks in preclinical validation and moving towards more efficient validation of promising drug treatment strategies to accelerate the pace of Fragile X research and treatment development.
adipisicing irure consequat fugiat ipsum enim ipsum incididunt in enim anim ad sint veniam ipsum enim voluptate nostrud ad voluptate minim pariatur laborum commodo dolore aute esse quis ex occaecat pariatur excepteur nisi adipisicing fugiat ipsum aliqua eu commodo est sunt fugiat cillum adipisicing commodo et proident ipsum culpa eiusmod voluptate Lorem cupidatat voluptate nulla duis dolor eu culpa adipisicing tempor proident eu laborum non officia fugiat laborum pariatur ea consequat laboris nisi sint ea commodo commodo ex dolore eiusmod do